Amundi Has $2.27 Million Position in PROCEPT BioRobotics Corporation $PRCT

Key Points

• Amundi increased its PROCEPT BioRobotics stake by 329.8% in the second quarter, acquiring 77,145 additional shares for a total position valued at approximately $2.27 million. Institutional investors now own 89.46% of the company.
• PROCEPT reported quarterly revenue of $94.5 million, up 19.3% year over year and above estimates, but posted a $0.47 loss per share and maintained negative profitability metrics. The stock recently traded near $20.38, well below its one-year high of $40.10.
• Analyst sentiment is cautious, with a consensus “Hold” rating and a $25.09 target price; several firms recently downgraded the stock. The company also faces securities-class-action allegations related to inventory issues and weaker handpiece sales, though the claims have not been proven.

Amundi grew its stake in shares of PROCEPT BioRobotics Corporation (NASDAQ:PRCT - Free Report) by 329.8% in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 100,539 shares of the company's stock after acquiring an additional 77,145 shares during the period. Amundi owned 0.18% of PROCEPT BioRobotics worth $2,270,000 at the end of the most recent quarter.

Other institutional investors have also added to or reduced their stakes in the company. Versant Capital Management Inc increased its stake in PROCEPT BioRobotics by 994.5% during the 2nd quarter. Versant Capital Management Inc now owns 1,193 shares of the company's stock worth $27,000 after acquiring an additional 1,084 shares during the period. Nykredit A S bought a new stake in PROCEPT BioRobotics during the second quarter worth $27,000. Caitong International Asset Management Co. Ltd boosted its holdings in shares of PROCEPT BioRobotics by 436.3% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 917 shares of the company's stock valued at $29,000 after purchasing an additional 746 shares in the last quarter. Center for Financial Planning Inc. acquired a new stake in shares of PROCEPT BioRobotics in the 4th quarter valued at $40,000. Finally, Cache Advisors LLC bought a new position in shares of PROCEPT BioRobotics in the 1st quarter valued at $42,000. 89.46% of the stock is currently owned by institutional investors.

PROCEPT BioRobotics Stock Performance

PRCT opened at $20.38 on Monday. The business has a 50 day simple moving average of $20.24 and a two-hundred day simple moving average of $23.43. The firm has a market capitalization of $1.17 billion, a price-to-earnings ratio of -10.51 and a beta of 0.91. The company has a debt-to-equity ratio of 0.15, a current ratio of 6.55 and a quick ratio of 5.35. PROCEPT BioRobotics Corporation has a one year low of $16.67 and a one year high of $40.10.

PROCEPT BioRobotics (NASDAQ:PRCT - Get Free Report) last announced its quarterly earnings results on Tuesday, August 4th. The company reported ($0.47) EPS for the quarter, missing analysts' consensus estimates of ($0.46) by ($0.01). PROCEPT BioRobotics had a negative return on equity of 30.62% and a negative net margin of 32.53%.The business had revenue of $94.50 million during the quarter, compared to analysts' expectations of $92.77 million. During the same period in the previous year, the business earned ($0.35) EPS. The business's revenue was up 19.3% compared to the same quarter last year. Analysts predict that PROCEPT BioRobotics Corporation will post -1.67 EPS for the current year.

Trending Headlines about PROCEPT BioRobotics

Here are the key news stories impacting PROCEPT BioRobotics this week:

• Negative Sentiment: Multiple firms, including Kaplan Fox, Hagens Berman and others, say a securities class action has been filed on behalf of investors who purchased PRCT shares from February 28, 2024, through February 25, 2026. The lead-plaintiff deadline is September 22, 2026. Kaplan Fox class action announcement
• Negative Sentiment: The allegations center on purportedly undisclosed inventory problems, weaker-than-expected handpiece sales and repeated late-quarter bulk discounts that allegedly left customers with excess inventory. Hagens Berman said the disclosures contributed to an approximately 18% stock decline; the claims have not been proven in court. Hagens Berman securities-fraud lawsuit announcement
• Neutral Sentiment: Three executive vice presidents reported small stock sales totaling $21,851. The transactions represented less than 0.4% of each executive’s holdings and were made to cover tax withholding on vested equity awards, limiting their significance as a signal of management’s outlook. SEC insider transaction filing
• Neutral Sentiment: A report showing zero short interest and a zero-day days-to-cover ratio appears inconsistent with the surrounding data and is unlikely to provide a meaningful trading signal.

Insider Transactions at PROCEPT BioRobotics

In other news, CEO Larry Wood acquired 23,900 shares of the stock in a transaction on Friday, August 7th. The stock was acquired at an average price of $20.85 per share, with a total value of $498,315.00. Following the completion of the transaction, the chief executive officer owned 23,900 shares of the company's stock, valued at $498,315. This represents a ∞ increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Insiders sold a total of 1,043 shares of company stock valued at $21,851 in the last ninety days. 4.00% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

Several research analysts have recently issued reports on the company. Leerink Partners downgraded PROCEPT BioRobotics from an "outperform" rating to a "market perform" rating and lowered their price objective for the company from $31.00 to $29.00 in a research note on Thursday, June 11th. Robert W. Baird set a $20.00 price objective on shares of PROCEPT BioRobotics in a research report on Wednesday, August 5th. UBS Group lowered PROCEPT BioRobotics from a "buy" rating to a "neutral" rating and set a $20.00 target price on the stock. in a research note on Tuesday, July 28th. Weiss Ratings reaffirmed a "sell (e+)" rating on shares of PROCEPT BioRobotics in a report on Friday, July 17th. Finally, William Blair cut shares of PROCEPT BioRobotics from an "outperform" rating to a "market perform" rating in a research report on Wednesday, August 5th. One analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, ten have given a Hold rating and two have given a Sell rating to the company. According to MarketBeat.com, PROCEPT BioRobotics has a consensus rating of "Hold" and a consensus target price of $25.09.

PROCEPT BioRobotics Company Profile

PROCEPT BioRobotics Corporation is a medical technology company focused on developing and commercializing robotic solutions for urologic care. The company's primary focus is the treatment of benign prostatic hyperplasia (BPH), a noncancerous enlargement of the prostate that can cause urinary symptoms.

Its flagship product is the AQUABEAM Robotic System, which uses image guidance, robotics, and high-velocity waterjet technology to remove targeted prostate tissue without the use of a traditional cutting instrument.

Want to see what other hedge funds are holding PRCT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for PROCEPT BioRobotics Corporation (NASDAQ:PRCT - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.